University of California, San Francisco Logo

University of California, San Francisco | About UCSF | Search UCSF | UCSF Medical Center

Home > SFGH PHP Grand Rounds > MDR-XDR Tuberculosis > Friedland > Slides
Multiple and Extensively Drug-Resistant Tuberculosis (M & XDR TB) and HIV
Slide 1.

Gerald Friedland
Slide 1.

Slide 2.

Multiple Drug Resistant MDR TB First-Line TB Drugs
Slide 3.

Extensively Drug Resistant XDR TB Second-Line Drugs
Slide 4.

Worldwide Emergence of XDR TB, 2000-4
Slide 5.

Global Estimates
Slide 6.

Countries with XDR-TB Confirmed cases
Slide 7.

49 cases XDR TB in US 1993-2006
Slide 8.

KwaZuluNatal-Tugela Ferry-2001-2005
Slide 9.

Tugela Ferry
Slide 10.

Slide 11
Slide 11.

Medical Setting-COSH
Slide 12.

Outcomes in TB/HIV Integration Study-12 mos
Slide 13.

Outcomes in TB/HIV Integration Study-12 mos
Slide 15.

Slide 15
Slide 16.

XDR TB Patient Characteristics (n=53)
Slide 16.

Slide 17.

Slide 18.

Nosocomial Transmission of XDR TB
Slide 19.

Hospital Acquired XDR-TB
Slide 20.

Further Support for Nosocomial Transmission and Exogenous Superinfection
Slide 21.

Updated Figures from Tugela Ferry
Slide 22.

Is MDR & XDR TB Widespread in South Africa and Beyond?
Slide 23.

Cumulative Number of Health Care Facilities with >= 1 Case of XDR-TB
Slide 24.

Evolution of Drug Resistance in KZN Strain Family
Slide 25.

Etiology of XDR TB Epidemic in KwaZuluNatal
Slide 26.

Future Projections Tugela Ferry (2007-2012)
Slide 27.

What Can Be Done in the Short Term to Reduce the Impact of XDR TB Epidemic?
Slide 28.

XDR TB Cases Averted over the Next Five Years
Slide 29.

Efficacy of Rapidly Available Strategies to Reduce Nosocomial Transmission
Slide 30.

M/XDR TB Is A Wake Up Call
Slide 31.

TF CARES Tugela Ferry Care and Research Collaboration
Slide 32.